- Home
- UK: +44 (0)1980 753002
- USA: +1 (857) 241 3897
- info@kalvista.com
Creating a new generation of small molecule protease inhibitors
KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet needs.
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need.
KalVista continues to investigate additional proteases as potential therapeutic targets to fully exploit its research expertise and expand its portfolio.
The Company features an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.
News
KalVista Announces Initiation of a Phase 1 Clinical Trial of KVD818 for the Treatment of Hereditary Angioedema
11 August 2016 Read more...
Carbylan Therapeutics and KalVista Pharmaceuticals Conference Call to Discuss Proposed Transaction
22 June 2016 Read more...